Michael Grissinger appointed as new Chairman of AnaCardio
PRESS RELEASE Stockholm, Sweden, June 3, 2024 AnaCardio, a Swedish clinical-stage biopharmaceutical company focusing on developing novel contractile agents to treat patients with heart failure, announces today the appointment of Michael Grissinger, B.S M.B.A. as new chairman of the board.Michael has had a long and successful career in the pharmaceutical industry, leading large value business development transactions across multiple therapeutic areas and products. Michael spent more than two decades at Johnson & Johnson, holding positions of Vice President and Head, Worldwide